The median duration of the overall survival (OS) and progression-free survival (PFS) was 14.0 mo and 6.13 mo, respectively. was an active and safe treatment option for patients failing oxaliplatin-based therapy[20]. The role of bevacizumab in combination with FL as a third-line treatment was studied in a phase II trial Continue Reading